Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap |
|---|
| Enterprise Value |
|---|
| Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
PF PFE PFIZER INC FY ended Feb 19, 2026 | $27.96 | $159.36B | $176.96B | $62.58B | $15.48B | $7.77B | 20.56x | 2.55x | 9.71x |
LL LLY ELI LILLY & Co FY ended Feb 09, 2026 | $1,174.61 | $1.11T | $1.16T | $65.18B | $28.02B | $20.64B | 51.18x | 16.96x | 40.66x |
BM BMY BRISTOL MYERS SQUIBB CO FY ended Feb 04, 2026 | $66.58 | $136.00B | $156.99B | $48.19B | $14.61B | $7.05B | 19.24x | 2.82x | 9.39x |
JN JNJ JOHNSON & JOHNSON FY ended Feb 06, 2026 | $268.04 | $645.95B | $703.36B | $94.19B | $37.95B | $26.80B | 24.30x | 6.86x | 17.67x |
AB ABBV AbbVie Inc. FY ended Feb 10, 2026 | $255.48 | $451.46B | $508.66B | $61.16B | $17.62B | $4.23B | 108.25x | 7.38x | 24.66x |
AM AMGN AMGEN INC FY ended Feb 10, 2026 | $432.42 | $233.78B | $260.45B | $36.75B | $14.04B | $7.71B | 30.39x | 6.36x | 18.55x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 18.87x | 6/6 | $94.43B | $21.88 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 7.16x | 6/6 | $233.75B | $54.17 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 42.32x | 6/6 | $266.16B | $61.68 | Included in the active peer mix. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
PF PFE PFIZER INC FY ended Feb 19, 2026 | $27.96 | $159.36B | $176.96B | $62.58B | $15.48B | $7.77B | 20.56x | 2.55x | 9.71x |
LL LLY ELI LILLY & Co FY ended Feb 09, 2026 | $1,174.61 | $1.11T | $1.16T | $65.18B | $28.02B | $20.64B | 51.18x | 16.96x | 40.66x |
BM BMY BRISTOL MYERS SQUIBB CO FY ended Feb 04, 2026 | $66.58 | $136.00B | $156.99B | $48.19B | $14.61B | $7.05B | 19.24x | 2.82x | 9.39x |
JN JNJ JOHNSON & JOHNSON FY ended Feb 06, 2026 | $268.04 | $645.95B | $703.36B | $94.19B | $37.95B | $26.80B | 24.30x | 6.86x | 17.67x |
AB ABBV AbbVie Inc. FY ended Feb 10, 2026 | $255.48 | $451.46B | $508.66B | $61.16B | $17.62B | $4.23B | 108.25x | 7.38x | 24.66x |
AM AMGN AMGEN INC FY ended Feb 10, 2026 | $432.42 | $233.78B | $260.45B | $36.75B | $14.04B | $7.71B | 30.39x | 6.36x | 18.55x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 18.87x | 6/6 | $94.43B | $21.88 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 7.16x | 6/6 | $233.75B | $54.17 | Included in the active peer mix. |
Price / Earnings PEActive | Equity Multiple | 42.32x | 6/6 | $266.16B | $61.68 | Included in the active peer mix. |